Thymoglobulin Related Published Studies
Well-designed clinical trials related to Thymoglobulin (Anti-Thymocyte Globulin)
Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. [2010.11]
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. [2010.06.27]
A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. [2010.01]
Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. [2009.11]
A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. [2008.10.15]
Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. [2008.07.15]
CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. [2008.06]
A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. [2008.03]
Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection. [2008.01]
Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. [2008.01]
A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. [2008.01]
Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. [2007.11]
Well-designed clinical trials possibly related to Thymoglobulin (Anti-Thymocyte Globulin)
A randomized, double-blind, placebo-controlled, multicenter study of rabbit ATG
in the prophylaxis of acute rejection in lung transplantation. [2014]
Clofarabine +/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. [2011.06]
Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. [2011.01]
Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy
after lung transplantation. [2010]
Clinical application of Cordyceps sinensis on immunosuppressive therapy in renal transplantation. [2009.06]
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. [2009.06]
No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study. [2009.02.27]
A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. [2008.12]
Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: Five-year outcomes. [2008.11]
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. [2008.08.15]
Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. [2007.09.27]
Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. [2007.06.15]
Very early steroid withdrawal in simultaneous pancreas-kidney transplants. [2007.03]
Other research related to Thymoglobulin (Anti-Thymocyte Globulin)
Depleting antibody induction in simultaneous pancreas-kidney transplantation: a
prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte
globulin. [2014]
Impact of anti-thymocyte globulin during immunosuppression induction in patients
with hepatitis C after liver transplantation. [2014]
In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit
anti-thymocyte globulin induces B cell depletion and regeneration, which
associates with a high incidence of de novo donor-specific anti-HLA antibody
development. [2013]
Anti-thymocyte globulins for post-transplant graft-versus-host disease
prophylaxis-A systematic review and meta-analysis. [2013]
Randomized phase II trial comparing two dose levels of thymoglobulin in patients
undergoing unrelated donor hematopoietic cell transplant. [2012]
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host
disease after allogeneic stem cell or bone marrow transplantation in adults. [2012]
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. [2011.12.05]
Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review. [2011.06]
Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. [2011.03]
Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. [2011.03]
Addition of anti-CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25-positive population. [2011.03]
A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation. [2011.01]
Human CD4(+)CD25(+) Cells in Combination with CD34(+) Cells and Thymoglobulin to Prevent Anti-hematopoietic Stem Cell T Cell Alloreactivity. [2011.01]
A comparison of Jurkat cell-reactive anti-T lymphocyte globulin and fetal anti-thymocyte globulin preparations in the treatment of aplastic anemia. [2011]
Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. [2010.12.27]
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. [2010.12]
Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study. [2010.11]
Reduced intensity conditioning with fludarabin, oral busulfan and thymoglobulin allows long term disease control and low transplant related mortality in patients with hematological malignancies. [2010.09.15]
A review of the evidence for use of thymoglobulin induction in renal transplantation. [2010.06]
Advances in umbilical cord transplantation: the role of thymoglobulin/ATG in cord blood transplantation. [2010.06]
Successful engraftment with fludarabine, cyclophosphamide and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multi-center study. [2010.05.25]
Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. [2010.05]
Induction with basiliximab plus thymoglobulin is effective and safe in old-for-old renal transplantation: six-month results of a prospective clinical study. [2010.05]
Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. [2010.04.16]
Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance
immunosuppression) versus daclizumab in living donor renal transplantation. [2010]
A prospective, randomized, multicenter study evaluating early corticosteroid
withdrawal with Thymoglobulin in living-donor kidney transplantation. [2010]
Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit
anti-thymocyte globulin, given on day+7 after alternative donor transplants. [2010]
Continuous infusion of thymoglobulin for induction therapy in pediatric heart transplant recipients; experience and outcomes with a novel strategy for administration. [2009.08]
Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. [2009.07.30]
Thymoglobulin--new approaches to optimal outcomes. [2009.07]
Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. [2009.05.27]
New trends in transplantation: the use of Thymoglobulin. [2009.03]
Impact of polyclonal anti-thymocyte globulins on the expression of adhesion and inflammation molecules after ischemia-reperfusion injury. [2009.03]
Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. [2009.02]
Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database. [2009]
Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation. [2008.12]
Induction treatment with low-dose thymoglobulin or basiliximab in renal transplants from older donors. [2008.11]
Other possibly related research studies
A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. [2010.09]
Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation. [2010.07.26]
Adenovirus infections in pediatric small bowel transplant recipients. [2010.07.27]
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. [2010.05.10]
Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. [2010.03.27]
Pancreas transplantation: experience at University of Texas, Houston. [2010.01]
Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. [2010.01]
Outcome of exfoliative rejection after isolated intestinal transplantation in an adult: case report. [2010.01]
Graft-vs-host disease after small bowel transplantation in children. [2010.02]
Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. [2010.02.15]
Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. [2010.04.27]
Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients. [2010.05]
New immunosuppressive protocols with the advent of novel biological drugs. [2009.08.15]
[Clinical course of high and low immunological risk renal transplant receptors subjected to different immunosuppressive treatments] [2009]
Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. [2009.12]
Active management of post-renal transplantation BK virus nephropathy: preliminary report. [2009.09]
Pancreas transplantation alone in children: a case report. [2009.11]
Cytomegalovirus infection renal transplant recipients: risk factors and outcome. [2009.07]
Very low-grade proteinuria at 3 months posttransplantation is an earlier marker of graft survival. [2009.07]
Histological findings of early graft biopsies in old donor renal transplant patients receiving induction therapy. [2009.07]
[Immunosuppression after liver transplantation] [2009.09]
Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results. [2009.07.27]
In vivo characterization of rabbit anti-mouse thymocyte globulin: a surrogate for rabbit anti-human thymocyte globulin. [2009.07.27]
Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. [2009.08]
The case for pancreas after kidney transplantation. [2009.08]
Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. [2009.06]
Rapid discontinuation of corticosteroids in pediatric renal transplantation. [2009.08]
Steroid withdrawal in simultaneous pancreas-kidney transplantation: a 7-year report. [2009.04]
New approaches to de novo immunosuppression and steroid elimination. [2008.12]
Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. [2009.04.15]
Treatment-dependent loss of polyfunctional CD8+ T-cell responses in HIV-infected kidney transplant recipients is associated with herpesvirus reactivation. [2009.04]
Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation. [2010.01]
Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. [2009.06]
Donor T-cell-mediated pancytopenia after haploidentical hematopoietic stem cell transplant for severe combined immunodeficiency. [2009.02]
Outcome predictors in African-American deceased-donor renal allograft recipients. [2009.08]
Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. [2009.01.27]
Antibodies to glycosylphosphatidyl-inositol anchored proteins (GPI-AP) in antithymocyte and antilymphocyte globulin: possible role for the expansion of GPI-AP deficient cells in aplastic anemia. [2009.09]
Intestine and multivisceral transplantation in the United States: a report of 20-year national registry data (1990-2009). [2009]
Early and late humoral rejection: a clinicopathologic entity in two times. [2008.11]
|